Vertex EVP sells 1,751 shares under trading plan

Vertex Pharmaceuticals executive Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer, reported two stock transactions in February 2026.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Edward Morrow Atkinson III, EVP and Chief Technical Operations Officer, reported two stock transactions in February 2026. On February 10, 2026, he disposed of 872 shares of common stock to cover tax obligations at a price of $468.41 per share. On February 11, 2026, he executed an open-market sale of 1,751 shares of common stock at $460.43 per share, made under a company-approved Rule 10b5-1 trading plan entered into on August 11, 2025. After these transactions, he directly owned 22,046 shares of Vertex common stock.

Insider Trade Summary

Net Seller: 1,751 shares

Net Sell 2 txns

Insider Atkinson Edward Morrow III

Role EVP, Chief Technical Ops. Off.

Sold 1,751 shs ($806K)

Type	Security	Shares	Price	Value
Sale	Common Stock	1,751	$460.43	$806K
Exercise Price or Tax Liability	Common Stock	872	$468.41	$408K

Holdings After Transaction: Common Stock — 22,046 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did VRTX executive Edward Atkinson report?

Edward Morrow Atkinson III reported a sale of 1,751 Vertex common shares. The shares were sold in an open-market transaction at $460.43 per share, following a separate tax-withholding share disposition the prior day.

At what prices did the VRTX insider transactions occur?

The tax-withholding disposition occurred at $468.41 per share, while the open-market sale was executed at $460.43 per share. Both transactions involved Vertex Pharmaceuticals common stock and were reported as direct ownership changes.

How many VRTX shares does Edward Atkinson own after these trades?

After the reported transactions, Edward Morrow Atkinson III directly owns 22,046 shares of Vertex common stock. This figure reflects both the tax-withholding disposition and the subsequent open-market sale reported in the Form 4 filing.

Was the VRTX insider stock sale under a Rule 10b5-1 plan?

Yes. The 1,751-share open-market sale was made under a company-approved Rule 10b5-1 trading plan. The filing notes that this plan was entered into on August 11, 2025, before the February 2026 transaction.

What does the tax-withholding transaction in the VRTX Form 4 represent?

The 872-share transaction coded “F” represents a tax-withholding disposition. This means shares were delivered to satisfy tax obligations or exercise costs, rather than being an open-market sale to third-party buyers.

What role does Edward Atkinson hold at Vertex Pharmaceuticals (VRTX)?

Edward Morrow Atkinson III serves as Executive Vice President and Chief Technical Operations Officer at Vertex Pharmaceuticals. The Form 4 identifies him as an officer of the company, rather than a director or 10% owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:50 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Atkinson Edward Morrow III

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Technical Ops. Off.

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		F		872	D	$468.41	23,797	D
Common Stock	02/11/2026		S(1)		1,751	D	$460.43	22,046	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Mr. Atkinson's company approved trading plan under Rule 10b5-1, which was entered into on 08/11/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.